Kaidy Shares: Robot-related products are still in the development stage and cannot generate revenue in the short term
KaiDi Co. announced that its robot-related products are still in the development phase and will not generate revenue in the short term. The company's stock experienced significant price fluctuations, prompting this clarification. Separately, Hanyu Pharmaceutical signed a framework agreement for peptide raw material sales amounting to at least 327 million yuan, and the news also mentioned global free access to ChatGPT Plus and other unrelated financial news. AI